Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 10/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13650093 | 0.96 | SIRT1 (0.55) | SIRT1POLBMEN1KMT2ANPC1 | |
| SCHEMBL13650104 | 0.93 | SIRT1 (0.45) | SIRT1POLBMEN1KMT2ANPC1 | |
| SCHEMBL13650095 | 0.90 | MEN1 (0.43) | SIRT1POLBMEN1KMT2ANPC1 | |
| SCHEMBL13650103 | 0.85 | NCOA1 (0.52) | POLBMEN1KMT2ANPC1TDP1 | |
| SCHEMBL13650085 | 0.83 | CFTR (0.56) | SIRT1POLBMEN1KMT2ANPC1 | |
| SCHEMBL13650098 | 0.83 | CFTR (0.53) | SIRT1POLBMEN1KMT2ANPC1 | |
| SCHEMBL13650092 | 0.82 | SIRT1 (0.48) | SIRT1POLBMEN1KMT2ANPC1 | |
| SCHEMBL13650083 | 0.78 | CFTR (0.49) | SIRT1POLBMEN1KMT2ANPC1 | |
| SCHEMBL13650082 | 0.77 | SIRT1 (0.50) | SIRT1POLBMEN1KMT2ACFTR | |
| SCHEMBL13650106 | 0.74 | SIRT1 (0.49) | SIRT1POLBMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253799-A1 | DIVALENT HYDRAZIDE COMPOUND CONJUGATES FOR INHIBITING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253799-A1 | DIVALENT HYDRAZIDE COMPOUND CONJUGATES FOR INHIBITING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, SLC26A3 | SIRT1 3338/4885POLB 3817/4885MEN1 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.